Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049230 · ClinicalTrials.gov registry record · NA
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
A NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT01049230 is a NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01049230, a NA study of Germ Cell Tumor and Central Nervous System Germ Cell Tumor, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to determine if radiation using proton beam therapy will kill the germ cell tumor in the participant's central nervous system. This type of radiation has been used previously on many patients with different types of cancers. There are two types of external radiation treatments, proton beam and photon beam. In this study we will be examining the effects of proton beam radiation therapy. Studies have suggested that this kind of radiation can spare normal tissue more than photon radiation therapy. The physical characteristics of proton beam radiation let the doctor safely increase the amount of radiation delivered to the tumor. We believe that proton beam therapy will potentially reduce side effects that participants would normally experience with photon radiation therapy.
Conditions Studied
Interventions
- RADIATION Proton Beam radiation
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-06 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049230
The ClinicalTrials.gov registry entry for NCT01049230 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (87% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam radiation is the first listed.
NCT01049230 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01049230 about?
NCT01049230 is a clinical study titled "Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors". The purpose of this research study is to determine if radiation using proton beam therapy will kill the germ cell tumor in the participant's central nervous system. This type of radiation has been used previously on many patients with different types of cancers. There are two types of external radia...
What is the current status of trial NCT01049230?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2010-06. Estimated completion is 2027-12-31.
What conditions does trial NCT01049230 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Central Nervous System Germ Cell Tumor.
What interventions are being tested in trial NCT01049230?
The interventions under investigation include: Proton Beam radiation (RADIATION).
Who is sponsoring clinical trial NCT01049230?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049230 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Explore more on PlainTrial
Germ Cell Tumor
All registered trials for this condition
Central Nervous System Germ Cell Tumor
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.